Argenx to Buy Forte Biosciences for $2.2 Billion

The acquisition of Forte Biosciences by Argenx for $2.2 billion is set to reshape the landscape of immunology therapeutics. This transaction involves the transfer of an entire pipeline centered on autoimmune research, most notably the anti-CD122 antibody candidate known as FB102, which is currently in phase 2 trials for conditions such as vitiligo. Argenx initiated this purchase to bolster its specialized portfolio, according to details provided by Yahoo Finance, STAT, and The Wall Street Journal.

The deal effectively brings the clinical-stage asset FB102 under the ownership of Argenx, signaling an effort to consolidate resources within the autoimmune drug sector. Market analysts have already begun to react to the terms of the agreement. Specifically, TD Cowen issued a downgrade on Forte Biosciences stock following the announcement of the acquisition.

While the financial terms of the deal are settled at $2.2 billion, the broader market implications remain the primary point of interest. Regulatory timelines and the finalization of the transition for the research staff and clinical trials are not explicitly detailed in the current coverage.